Cellusion welcomes Stella and Toru as new board members

TOKYO (Aug 31, 2021)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) announced to welcome Stella Yeh and Toru J. Seo, Ph.D. as our new board members. Cellusion also announce the retirement of Hans Tai from our board member. Under this new management team, Cellusion will accelerate to develop novel regenerative therapy for all bullous keratopathy patients in the world.

For further information: please ask us through contact form in our website.

<About Stella Yeh>
After her Master study on city planning at University of Pennsylvania and MBA at University of Pittsburgh, Stella has chaired the boards of several companies, and brings a broad spectrum of skills from her background: over ten years advising angel investors, developing corporate strategy and strategic alliances for publicly-listed companies, managing OEM (for ASUSTeK), and investor relations. She is also known as a serial entrepreneur of a venture capital founder and a chairman of a Taiwanese biotech. She has served Industrial Technology Investment Corporation as a vice president since 2019. With the retirement of Mr. Hans, she has accepted to join Cellusion management team.

<About Toru J. Seo, Ph.D.>
After his Ph.D. from Wake Forest University, Toru joined a faculty in Columbia University Medical Center. From 2007, he decided to pursue a R&D career in the leading industries such as GSK, Merck, Taisho and Pfizer where his roles came to include project leader, global scientific committee member, team lead, and later on in business development and corporate strategic planning. In 2019, he became an APAC head of Search and Evaluation, Worldwide Business Development, Chief Business Office, and served the role until 2021. After leaving Pfizer, he founded his own drug discovery biotech and investment farm, and has served CEO of LUCIDAIM Co. Ltd., advisor of biotech ventures and VCs while being a visiting professor of Osaka University and a visiting lecturer of Waseda Business School.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/